Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Intensive induction chemotherapy and HMA/VEN showed similar adjusted survival outcomes in older patients with NPM1-mutant AML. Composite complete remission rates were comparable between IC and HMA/VEN ...

Serial post-transplant chimerism assessment provided more reliable prognostic insight than a single early measurement.

A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory and relapsed disease, addressing poor outcomes in patients with TP53 ...

SLS and ATNM are heading into the AACR summit with fresh leukemia-focused data catalysts expected to refocus investor attention. ・Sellas will present preclinical AML data on SLS009, demonstrating ...

Leukemia starts in the bone marrow and spreads through the blood. Lymphoma originates in the spleen or lymph nodes and spreads through the lymph vessels. Acute myeloid leukemia (AML) is considered the ...

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age ...

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that suppress their growth ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...